Vancomycin
- Generic Name
- Vancomycin
- Brand Names
- Firvanq, Vancocin
- Drug Type
- Small Molecule
- Chemical Formula
- C66H75Cl2N9O24
- CAS Number
- 1404-90-6
- Unique Ingredient Identifier
- 6Q205EH1VU
- Background
Antibacterial obtained from Streptomyces orientalis. It is a glycopeptide related to ristocetin that inhibits bacterial cell wall assembly and is toxic to kidneys and the inner ear.
...
- Indication
Administered intravenously, vancomycin is indicated in adult and pediatric patients for the treatment of septicemia, infective endocarditis, skin and skin structure infections, bone infections, and lower respiratory tract infections. Administered orally, vancomycin is indicated in adult and pediatric patients for the treatment of Clostridium difficile-associ...
- Associated Conditions
- Clostridium Difficile Associated Diarrhea (CDAD), Enterocolitis caused by Staphylococcus aureus, Infection caused by staphylococci, Severe Staphylococcal infection
- Associated Therapies
- -
Fosfomycin Plus Imipenem for Treatment of Infective Endocarditis
- Conditions
- Interventions
- First Posted Date
- 2009-03-30
- Last Posted Date
- 2018-03-08
- Lead Sponsor
- Juan A. Arnaiz
- Target Recruit Count
- 50
- Registration Number
- NCT00871104
- Locations
- 🇪🇸
Hospital Gregorio Marañón, Madrid, Spain
🇪🇸Hospital Clínic of Barcelona, Barcelona, Catalonia, Spain
🇪🇸Hospital La Paz, Madrid, Spain
China Registration Study in Patients With Skin Infections
- First Posted Date
- 2008-10-15
- Last Posted Date
- 2015-03-09
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 265
- Registration Number
- NCT00772447
- Locations
- 🇨🇳
Research Site, Qingdao, China
Phase 2 Study of Safety, Efficacy, and Pharmacokinetics of Higher Doses of Daptomycin and Vancomycin in MRSA Bacteremia
- Conditions
- Interventions
- First Posted Date
- 2008-06-12
- Last Posted Date
- 2018-12-24
- Target Recruit Count
- 38
- Registration Number
- NCT00695903
- Locations
- 🇺🇸
Cleveland Clinic Foundation, Cleveland, Ohio, United States
🇺🇸East Carolina University, Greenville, North Carolina, United States
Microbiologic Response With Linezolid And Vancomycin In Ventilator-Associated Pneumonia Due To Methicillin Resistant Staphylococcus Aureus
- Conditions
- Interventions
- First Posted Date
- 2007-12-13
- Last Posted Date
- 2010-06-09
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 149
- Registration Number
- NCT00572559
- Locations
- 🇵🇷
Pfizer Investigational Site, San Juan, Puerto Rico
Clinical Efficacy of Intravenous Iclaprim Versus Vancomycin in the Treatment of Hospital-Acquired, Ventilator-Associated, or Health-Care-Associated Pneumonia
- Conditions
- Interventions
- First Posted Date
- 2007-10-15
- Last Posted Date
- 2009-02-13
- Lead Sponsor
- Arpida AG
- Target Recruit Count
- 135
- Registration Number
- NCT00543608
PAR-101/OPT-80 Versus Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD)
- Conditions
- Interventions
- First Posted Date
- 2007-05-03
- Last Posted Date
- 2017-04-21
- Target Recruit Count
- 535
- Registration Number
- NCT00468728
Meropenem Versus Meropenem Plus Glycopeptide in Patients With Febrile Neutropenia After Allogenic Blood Stem Cell Transplantation
- Conditions
- First Posted Date
- 2007-04-19
- Last Posted Date
- 2009-05-12
- Lead Sponsor
- PETHEMA Foundation
- Target Recruit Count
- 392
- Registration Number
- NCT00462878
- Locations
- 🇪🇸
Hospital Universitario de Canarias, Tenerife, Canarias, Spain
🇪🇸Hospital Central de Asturias, Oviedo, Asturias, Spain
🇪🇸Hospital Verge de la Cinta, Tortosa, Tarragona, Spain
Comparison of Teicoplanin and Vancomycin in Initial Empirical Antibiotic Regimen for Febrile Neutropenic Patients
- Conditions
- Interventions
- First Posted Date
- 2007-03-30
- Last Posted Date
- 2009-03-06
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 197
- Registration Number
- NCT00454272
- Locations
- 🇹🇷
Sanofi aventis administrative office, Istanbul, Turkey
Acute Renal Failure in the Surgical Intense Care Units - NTUH-SICU-ARF (NSARF) Study
- Conditions
- First Posted Date
- 2007-03-23
- Last Posted Date
- 2007-03-23
- Lead Sponsor
- National Taiwan University Hospital
- Target Recruit Count
- 300
- Registration Number
- NCT00451373
- Locations
- 🇨🇳
National Taiwan University Hospital, Taipei, Taiwan
TD-1792 in Gram-positive Complicated Skin and Skin Structure Infection
- First Posted Date
- 2007-03-02
- Last Posted Date
- 2021-01-20
- Lead Sponsor
- Theravance Biopharma
- Target Recruit Count
- 203
- Registration Number
- NCT00442832
- Locations
- 🇺🇸
Allan Churukian, National City, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.